NCT04272151 is a Phase 1, PHASE2 clinical trial of BCMA CAR-T cells in Multiple Myeloma, sponsored by Chongqing Precision Biotech Co., Ltd.

Who is sponsoring NCT04272151?

NCT04272151 is sponsored by Chongqing Precision Biotech Co., Ltd.

What drugs are being tested in NCT04272151?

Interventions in NCT04272151: BCMA CAR-T cells.

What condition does NCT04272151 study?

NCT04272151 studies Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell.

Is NCT04272151 still recruiting?

NCT04272151 is currently status unknown. Last updated 18 April 2023.

Last reviewed 2023-04-18 · How we verify

NCT04272151

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Status unknown Phase 1, PHASE2 Last updated 18 April 2023

What this trial tests

Phase 1, PHASE2 trial testing BCMA CAR-T cells in Multiple Myeloma in 40 participants. Status unknown.

Timeline

1 December 2019

Primary endpoint
31 December 2023

1 July 2024

Quick facts

Lead sponsor	Chongqing Precision Biotech Co., Ltd
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 December 2019
Primary completion	31 December 2023
Estimated completion	1 July 2024
Sites	1 location across China

Drugs / interventions tested

BCMA CAR-T cells — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →
Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
Neoplasm, Plasma Cell — all drugs for Neoplasm, Plasma Cell →

Sponsor

Chongqing Precision Biotech Co., Ltd — full company profile →

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma or Multiple Myeloma in Relapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2
Challenges and strategies associated with CAR-T cell therapy in blood malignancies.
Liu Z, Lei W, Wang H, Liu X, et al · · 2024 · cited 23× · PMID 38402232 · DOI 10.1186/s40164-024-00490-x
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT, Ye JC. · · 2021 · cited 21× · PMID 34301270 · DOI 10.1186/s13045-021-01109-y
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Shrivastava T, Van Rhee F, Al Hadidi S. · · 2023 · cited 10× · PMID 37359353 · DOI 10.2147/ott.s370880
Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers.
Rabbani SA, El-Tanani M, El-Tanani Y, Kumar R, et al · · 2025 · cited 1× · PMID 40981188 · DOI 10.3390/medsci13030190

Verify or expand the search:

Other trials of BCMA CAR-T cells

Trials testing the same drug.

NCT05712083 — A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma · Phase 2 · unknown
NCT04271644 — BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease · Phase 1, PHASE2 · recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Chongqing Precision Biotech Co., Ltd trials

Trials by the same sponsor.

NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04272151 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
Last refreshed: 18 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04272151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing